<DOC>
	<DOCNO>NCT02934269</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety , tolerability , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) CC-90006 follow administration single subcutaneous dos healthy subject .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , Pharmacodynamics CC-90006 Healthy Subjects</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerability , pharmacokinetic profile single-ascending dos CC-90006 healthy subject . This placebo-controlled , single-ascending dose study CC-90006 . Approximately 40 subject enrol . Five dose level plan . Each dose level enroll 8 subject assign randomly receive active CC-90006 ( 6 subject ) placebo ( 2 subject ) . Eligible subject check clinic site day dose ( Day -1 ) receive assign dose subcutaneous injection follow day ( Day 1 ) . Subjects discharge site Day 4 return visit Days 8 ( week 1 ) , 15 ( week 2 ) , 22 ( week 3 ) , 29 ( week 4 ) , 36 ( week 5 ) , 43 ( week 6 ) , 57 ( week 8 ) , 71 ( week 10 ) . Subjects also follow via phone call Day 105 ( week 15 ) . Safety assessment perform blood sample collect determination level CC-90006 blood .</detailed_description>
	<criteria>Healthy male and/or female subject age 18 55 year , body mass index ( BMI ) ≥ 18 ≤ 33 kg/m2 body weight ≥ 50 ≤ 90 kg screening . Females must surgically sterilize ( hysterectomy , bilateral oophorectomy , bilateral salpingooophorectomy ; proper documentation require ) least 6 month screen , postmenopausal ( defined 24 consecutive month without menses screen , folliclestimulating hormone [ FSH ] level &gt; 40 IU/L screening ) . Exposure/treatment investigational ( new chemical entity ) market drug biologic within 30 day precede first dose administration , five halflives investigational drug biologic , know ( whichever longer ) . Donation blood serum within 8 week first dose administration blood bank blood donation center . History alcohol drug abuse ( define current version DSM ) within 2 year first dose administration , positive alcohol drug screen . Vaccination within 30 day prior first dose administration plan receive vaccination course study ( include follow phone call Day 105 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Safety</keyword>
	<keyword>CC-90006</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Tolerability</keyword>
</DOC>